The suggested mechanisms linking OSA with ischaemic stroke include haemodynamic, neural, circadian, vascular, metabolic, inflammatory, and thrombotic processes.
Dr Maria Rita Lo Monaco (Catholic University of the Sacred Heart, Italy) and her team conducted a study that aimed to evaluate the prevalence of atrial fibrillation and obstructive sleep apnoea in participants with acute ischaemic stroke within 7 days of onset [1].
The researchers collected data retrospectively from 146 participants over 4 years, encompassing clinical, neurological, and cardiological evaluations. Various patient parameters were analysed, including age, sex, BMI, wake-up stroke, National Institutes of Health Stroke Scale (NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), Groningen Upper Extremity Motor Score (GUSS), Apnea-Hypopnea Index (AHI), oxygen desaturation index (ODI), OSA severity, atrial fibrillation, and other cardiac risk factors.
In the participants with ischaemic stroke, OSA prevalence was as high as 50%. The study further revealed that out of the 146 enrolled participants, 41 (28%) had documented episodes of atrial fibrillation. Notably, 22 participants (15%) were affected by both atrial fibrillation and OSA. This observed association was higher (15%) than expected when only considering each pathology separately (10%).
These results support the potential pathogenesis of apnoea-related hypoxia, which poses a significant risk of ischaemic stroke, especially in patients with atrial fibrillation. The findings underscore the importance of considering the co-existence of atrial fibrillation and OSA in stroke patients, as their association may indicate a pathogenic mechanism and influence treatment strategies to prevent future strokes.
- Lo Monaco MR, et al. Impact of sleep apnea and atrial fibrillation in patients with ischemic stroke. Session E-Posters in preventive cardiology, Heart Failure 2023, 20–23 May, Prague, Czechia.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Protein-bound uremic toxins predict HF events and death in patients with CKD Next Article
Letter from the Editor »
« Protein-bound uremic toxins predict HF events and death in patients with CKD Next Article
Letter from the Editor »
Table of Contents: HFA 2023
Featured articles
Chronic Heart Failure — What You Need to Know
Sacubitril/valsartan reduces natriuretic peptides in HF patients with ejection fraction >40%
Clinically relevant reduction in HF hospitalisation due to haemodynamic monitoring
TRACER-HF: Trientine reduced biomarkers up to 8 weeks
Dapagliflozin improves LAVI, LV mass, and concentration of natriuretic peptides after 6 months
NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
Novel Therapeutics in Cardiomyopathy
Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis
Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
What is New in Acute Heart Failure?
Standardised diuretic protocol significantly increases natriuresis in acute HF
Low concentrations of VEGF-C: a negative prognostic factor
Prevention and Comorbid Conditions of Heart Failure
VOICE-COVID-II : Alexa successful in SARS-CoV-2 symptoms screening
HF patients with metabolic dysfunction at high risk to develop depressive symptoms
Best of the Posters
Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients
Protein-bound uremic toxins predict HF events and death in patients with CKD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com